Innovative breakthroughs of monoclonal antibodies in tumor therapy: From “indiscriminate killing” to “precision guidance”

Funding

This work was supported by the Science and Technology Development Fund of the Tianjin Education Commission for Higher Education (2024ZD005).

Conflict of interest

Xianbin Kong is the Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

[1] Mee T, Kirkby NF, Defourny NN, Kirkby KJ, Burnet NG. The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: Results from the FORTY (favourable outcomes from Radiotherapy) project. Br J Radiol. 2023; 96(1152):20230334. doi: 10.1259/bjr.20230334

[2] Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024; 22(1):109. doi: 10.1186/s12964-023-01302-1

[3] Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduct Target Ther. 2024; 9(1):175. doi: 10.1038/s41392-024-01856-7

[4] Parvanian S, Ge X, Garris CS. Recent developments in myeloid immune modulation in cancer therapy. Trends Cancer. 2025; 11:365-375. doi: 10.1016/j.trecan.2024.12.003

[5] Sapio L, Naviglio S. Innovation through tradition: The current challenges in cancer treatment. Int J Mol Sci. 2022; 23(10):5296. doi: 10.3390/ijms23105296

[6] Chandana SR, Choudhury NJ, Dowlati A, et al. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. J Clin Oncol. 2024; 42(16):3001. doi: 10.1200/JCO.2024.42.16_suppl.3001

[7] De Miguel FJ, Gentile C, Feng WW, et al. Mammalian SWI/ SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023; 41(8):1516-1534.e9. doi: 10.1016/j.ccell.2023.07.005

[8] Theocharopoulos C, Lialios PP, Samarkos M, Gogas H, Ziogas DC. Antibody-drug conjugates: Functional principles and applications in oncology and beyond. Vaccines (Basel). 2021; 9(10):1111. doi: 10.3390/vaccines9101111

[9] Lv J, Wei Y, Yin JH, et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023; 29(6):1424-1436. doi: 10.1038/s41591-023-02369-6

[10] Pleiko K, Haugas M, Parfejevs V, et al. Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer. Mol Ther Nucleic Acids. 2023; 33:871-884. doi: 10.1016/j.omtn.2023.08.015

[11] Akbar R, Robert PA, Weber CR, et al. In silico proof of principle of machine learning-based antibody design at unconstrained scale. MAbs. 2022; 14(1):2031482. doi: 10.1080/19420862.2022.2031482

[12] Makowski EK, Kinnunen PC, Huang J, et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat Commun. 2022; 13(1):3788. doi: 10.1038/s41467-022-31457-3

[13] Ludwig SD, Bernstein ZJ, Agatemor C, et al. A versatile design platform for glycoengineering therapeutic antibodies. MAbs. 2022; 14(1):2095704. doi: 10.1080/19420862.2022.2095704

[14] Eiger D, Franzoi MA, Pondé N, et al. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: A systematic review and meta-analysis of six clinical trials. ESMO Open. 2020; 5(1):e000659. doi: 10.1136/esmoopen-2019-000659

[15] Song IW, Vo HH, Chen YS, et al. Precision oncology: Evolving clinical trials across tumor types. Cancers (Basel). 2023; 15(7):1967. doi: 10.3390/cancers15071967

[16] Smith SN, Schubert R, Simic B, et al. The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. Proc Natl Acad Sci U S A. 2021; 118(21):e2017925118. doi: 10.1073/pnas.2017925118

[17] Erfani A, Reichert P, Narasimhan CN, Doyle PS. Injectable hydrogel particles for amorphous solid formulation of biologics. iScience. 2023; 26(8):107452. doi: 10.1016/j.isci.2023.107452

[18] Deslignière E, Ollivier S, Ehkirch A, et al. Combination of IM-based approaches to unravel the coexistence of two conformers on a therapeutic multispecific mAb. Anal Chem. 2022; 94(22):7981-7989. doi: 10.1021/acs.analchem.2c00928

[19] Klich JH, Kasse CM, Mann JL, et al. Stable high-concentration monoclonal antibody formulations enabled by an amphiphilic copolymer excipient. Adv Ther (Weinh). 2023; 6(1):2200102. doi: 10.1002/adtp.202200102

[20] Gieber L, Muturi-Kioi V, Malhotra S, Sitlani A. Clinical and regulatory challenges and opportunities for monoclonal antibodies in low- and middle-income countries: Lessons from COVID-19 and beyond. Pharmaceut Med. 2023; 37(3):203-214. doi: 10.1007/s40290-023-00473-z

[21] Tang Z, Wang X, Tang M, et al. Overcoming the on-target toxicity in antibody-mediated therapies via an indirect active targeting strategy. Adv Sci (Weinh). 2023; 10(9):e2206912. doi: 10.1002/advs.202206912

[22] Yang J, Chaudhry BI, Yue AT, et al. The impact of biosimilar use on total cost of care and provider financial performance in the medicare oncology care model: A population-based simulation study. Adv Ther. 2024; 41(1):349-363. doi: 10.1007/s12325-023-02703-x

[23] Cohen HP, Turner M, McCabe D, Woollett GR. Future evolution of biosimilar development by application of current science and available evidence: The developer’s perspective. BioDrugs. 2023; 37(5):583-593. doi: 10.1007/s40259-023-00619-0